antalarmin

ant·a·lar·min

(ant-ă-larm'in),
Prototype small molecular weight corticotropin-releasing hormone or factor (CRH or CRF) antagonist that interacts with CRH type 1 receptors to inhibit behavioral and physical aspects of the stress response.
[ant- + alarm + in]
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats.
Belzung, "Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice," Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.
Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout.
Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rate.
In addition, loss of [CB.sub.1] induces aberrant CRH-driven endocrine activities leading to preterm labor in mice, Antalarmin hydrochloride, a selective CRH antagonist, is able to restore the normal parturition timing in [CB.sub.1] deficient mice, and enhanced corticosterone activity on days 14-18 induces preterm birth with impaired fetal growth in wild-type mice.
Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF 1 receptor antagonist antalarmin and by CRF1 receptor knockout.
Social stress increases tumor development: Effects of antalarmin a CRF type 1 receptor antagonist and nadolol a beta-adrenergic antagonist.
Subsequent research showed that the compound antalarmin, which blocks the corticotropin-releasing hormone receptor, impeded stress-induced reinstatement of drinking in the alcohol-preferring rats.
The NIMH is performing its own toxicology studies in collaboration with other federal institutes on a CRH antagonist developed within NIMH called antalarmin, he said.
The most widely studied agent in this new class is antalarmin, an experimental compound developed at the National Institutes of Health.
In a separate set of experiments, the researchers injected pregnant rats with antalarmin, a molecule that blocks CRH from docking on cells and triggering FasL production.
This latter effect was blocked by an agent that can interfere with the activity of the [CRF.sub.1] receptor (i.e., the [CRF.sub.1] receptor antagonist antalarmin) in msP rats but not Wistar rats.